Coronary Artery Bypass Surgery Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of IK-1001 to Evaluate Safety, Pharmacokinetics and Proof-of-concept Efficacy for Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft(CABG)Surgery
This clinical trial will investigate the safety and effectiveness of IK-1001 (the liquid
form of sodium sulfide) when used in Coronary Artery Bypass Graft (CABG) patients to
potentially reduce the damage done to the heart during surgery.
This study has 2 parts. Part 1 will first test 36 subjects at different doses (amount) of
the study drug. There will be 6 different groups of 6 subjects each that will receive the
study drug or a placebo. A placebo is a substance that will be prepared to look like the
study drug but will contain no active ingredients. In Part 1, five subjects from each group
will receive study drug (IK-1001) and one will receive a placebo. This first part of this
study is also a dose (amount) escalation. This means that each group will be receiving a
different dose of the study drug. The first group will receive the lowest dose, the second
group will receive a slightly higher dose, and the third group a slightly higher dose until
all six groups has been tested. You can not choose which group you will be in but prior to
starting each new dose level, the data (information) from the previous dose level will have
been reviewed by a group of qualified individuals to determine if it is safe to proceed to
the next highest dose level.
Part 2 will expand the study and will treat at least 158 (and up to 632) more subjects at a
dose level that has been deemed safe from information collected from Part 1. Subjects in
Part 2 of the study will have a 1 in 2 (50%) chance of receiving the study drug or placebo.
Whether the subject gets study drug or the placebo will be randomly assigned (like the toss
of a coin).
The study drug or placebo will be given as an intravenous infusion (into the vein) for six
hours while the subject is having their CABG surgery.
The subjects will be followed up for 6 months after their CABG surgery.
Status | Terminated |
Enrollment | 6 |
Est. completion date | April 2010 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: 1. Subjects must be 18 to 85 years of age 2. Subject is scheduled to undergo CABG surgery with cardiopulmonary bypass 3. Subjects at an increased risk for I/R mediated tissue damage: defined as subjects with = 30% but = 50% ejection fraction (as measured by echocardiography within 14 days of study enrollment) or who fulfill at least two of the following criteria: - Current or recent smoker (within last 6 months prior to screening) - Female - Diabetes mellitus (a history of diabetes, regardless of duration of disease or need for anti-diabetic agents) - History of non-disabling stroke, TIA, carotid endarterectomy - Re- CABG (H/O previous CABG surgery, on or off-pump) - Peripheral artery surgery or angioplasty - Recent MI (= 48 hours and = 6 weeks before surgery, non STEMI and STEMI infarcts as documented in the medical records of the subject) - History of congestive heart failure (NYHA CHF Class III or IV) - Renal dysfunction: creatinine clearance = 30mL/min but < 60mL/min calculated using Crockroft and Gault formula: Creatinine clearance (mL/min) = (140 - age) x weight (kg) (x 0.85 for females) (72 x serum creatinine) - Asymptomatic stenosis (= 50%) in = 1 carotid artery - Age > 65 years Exclusion Criteria: 1. Known sulfite allergy or sulphur drug allergy 2. Subjects who have received treatment for asthma within the past 12 months 3. Myocardial infarction occurring < 48 hours prior to surgery 4. Current cardiogenic shock, acute left ventricular rupture, ventricular septal rupture, or papillary muscle rupture 5. History of prior disabling stroke 6. Clinically relevant liver disease (defined as serum transaminases = 3 x upper limit of normal for local laboratory) 7. Poorly controlled diabetes mellitus (defined as HbA1c > 9.0%) 8. Planned concomitant cardiac valve or other surgery at time of CABG 9. Planned use of thiopental during anesthesia for CABG surgery 10. All females of child bearing potential (defined as having menses without an alternative medical cause during the last 12 months). Women who are pregnant (defined as a positive serum pregnancy test), breast-feeding or lactating are also excluded. 11. Ongoing alcohol or drug abuse 12. Any underlying medical or psychiatric condition that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the study 13. Subject has participated in another investigational drug or device study within 30 days prior to enrollment to the study. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Ashford Hospital | Ashford | South Australia |
Australia | Flinder Medical Center | Bedford Park | South Australia |
Australia | Austin Hospital | Heidelberg | Victoria |
Australia | Alfred Hospital | Melbourne | Victoria |
Australia | St. Vincents Hospital | Melbourne | Victoria |
Canada | Jewish General Hospital | Montreal | Quebec |
Canada | Royal Victoria Hospital - MUHC | Montreal | Quebec |
Canada | Boniface General Hospital | Winnepeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
Mallinckrodt |
Australia, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiac Troponin T | Day 1 through Day 4 | No | |
Secondary | Mortality | Study duration | Yes | |
Secondary | 12-Lead ECG | Periodically through study duration | No | |
Secondary | Urinalysis | Screening, and 6 month | No | |
Secondary | Echocardiography | Screening, 3 month and 6 month | No | |
Secondary | Blood Draws | Study duration | Yes | |
Secondary | Vital Signs | Study duration | Yes | |
Secondary | MRI | Screening, 1 month | No | |
Secondary | Adverse events | Study duration | Yes | |
Secondary | Serum levels of CK-MB | Day 1 through Day 4 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05139108 -
TEE Monitoring and the Incidence of Postoperative Acute Kidney Injury in Coronary Artery Bypass Grafting
|
||
Completed |
NCT04523064 -
POST-CABGDM: Empagliflozin in Perioperative CABG
|
Phase 4 | |
Not yet recruiting |
NCT05540249 -
Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG
|
N/A | |
Completed |
NCT01467232 -
IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting
|
Phase 2 | |
Completed |
NCT04631809 -
Computed Tomography Coronary Angiography in Patients With a Previous Coronary Artery Bypass Graft Surgery Trial
|
N/A | |
Completed |
NCT00073580 -
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
|
Phase 3 | |
Terminated |
NCT03346278 -
Text Message Intervention to Improve Cardiac Rehab Participation
|
N/A | |
Completed |
NCT00303641 -
Safety and Effectiveness of the Medtronic Resting Heart Bypass System in Heart Surgery Patients
|
Phase 1 | |
Completed |
NCT03823521 -
Observational Study to Investigate the Effects of Training on the Administration of Cardioplexolâ„¢
|
Phase 3 | |
Terminated |
NCT00789399 -
A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis
|
N/A | |
Completed |
NCT02592824 -
Glutamate for Metabolic Intervention in Coronary Surgery II
|
Phase 3 | |
Not yet recruiting |
NCT05079724 -
Acute Kidney Injury After Cardiac Surgery
|
||
Withdrawn |
NCT04379947 -
Preoperative Use of Fractional Flow Reserve in CABG Use and Effectiveness of FFR-based CABG in Real-life Practice
|
||
Recruiting |
NCT01386229 -
A Comparison of Etomidate and Ketamine for Anesthesia Induction in Coronary Artery Bypass Graft Surgery
|
Phase 4 | |
Completed |
NCT00653042 -
Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA
|
Phase 2 | |
Completed |
NCT00318227 -
Randomized Trial of a Liberal Versus a Restrictive Transfusion Strategy in Elderly Cardiac Surgery Patients
|
N/A | |
Completed |
NCT00372671 -
Evaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation Participation
|
Phase 3 | |
Completed |
NCT00209521 -
Comparison of AQUAVAN® Injection to DISOPRIVAN® Injectable Emulsion for Anesthesia During Coronary Artery Surgery
|
Phase 2 | |
Not yet recruiting |
NCT05396690 -
Safety and Efficacy of Remimazolam in OPCAB Surgery
|
N/A | |
Recruiting |
NCT05411445 -
Study of Role of Blood Microvescicles and Exosomes in Patients With Graft Occlusion After Aortocoronary Bypass Surgery
|